Inventor
KOLTUN ELENA S
US40 patents
⚠️ This page may combine multiple inventors who share the name “KOLTUN ELENA S”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
REVOLUTION MEDICINES INC
23 patentsUS10590090B2Mar 17, 2020
2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors
REVOLUTION MEDICINES INC28 citations92
US11952352B2Apr 9, 2024
Ras inhibitors
REVOLUTION MEDICINES INC6 citations85
US11608346B2Mar 21, 2023
Ras inhibitors
REVOLUTION MEDICINES INC9 citations85
US11566007B2Jan 31, 2023
Ras inhibitors
REVOLUTION MEDICINES INC10 citations85
US11739074B2Aug 29, 2023
Ras inhibitors
REVOLUTION MEDICINES INC9 citations84
US11690915B2Jul 4, 2023
Ras inhibitors
REVOLUTION MEDICINES INC9 citations82
US9957290B2May 1, 2018
Derivatives of amphotericin B
REVOLUTION MEDICINES INC8 citations82
US12465643B2Nov 11, 2025
Ras inhibitors
REVOLUTION MEDICINES INC1 citations74
US12280113B2Apr 22, 2025
Ras inhibitors
REVOLUTION MEDICINES INC2 citations74
US12202845B2Jan 21, 2025
Ras inhibitors
REVOLUTION MEDICINES INC3 citations74
US12252497B2Mar 18, 2025
Ras inhibitors
REVOLUTION MEDICINES INC3 citations73
US11168102B1Nov 9, 2021
Bicyclic heteroaryl compounds and uses thereof
REVOLUTION MEDICINES INC5 citations70
US12409225B2Sep 9, 2025
Ras inhibitors
REVOLUTION MEDICINES INC0 citations62
US12403196B2Sep 2, 2025
Ras inhibitors
REVOLUTION MEDICINES INC0 citations62
US12384750B2Aug 12, 2025
Ras inhibitors
REVOLUTION MEDICINES INC0 citations62
US11673896B2Jun 13, 2023
Pyridine compounds as allosteric SHP2 inhibitors
REVOLUTION MEDICINES INC1 citations61
US12565476B2Mar 3, 2026
2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors
REVOLUTION MEDICINES INC0 citations60
US11702411B2Jul 18, 2023
Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors
REVOLUTION MEDICINES INC0 citations60
US11661401B2May 30, 2023
2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors
REVOLUTION MEDICINES INC0 citations60
US12365688B2Jul 22, 2025
Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors
REVOLUTION MEDICINES INC0 citations59
US12258366B2Mar 25, 2025
Bicyclic heteroaryl compounds and uses thereof
REVOLUTION MEDICINES INC0 citations59
US11739093B2Aug 29, 2023
Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors
REVOLUTION MEDICINES INC1 citations59
US11673901B2Jun 13, 2023
Polycyclic compounds as allosteric SHP2 inhibitors
REVOLUTION MEDICINES INC0 citations47
EXELIXIS INC
5 patentsUS7803839B2Sep 28, 2010
Azetidines as MEK inhibitors for the treatment of proliferative diseases
EXELIXIS INC46 citations95
US7915250B2Mar 29, 2011
Azetidines as MEK inhibitors for the treatment of proliferative diseases
EXELIXIS INC22 citations91
US8362002B2Jan 29, 2013
Azetidines as MEK inhibitors for the treatment of proliferative diseases
EXELIXIS INC12 citations83
US8053454B2Nov 8, 2011
Pyridopyrimidinone inhibitors of PIM-1 and/or PIM-3
EXELIXIS INC4 citations62
US11597699B2Mar 7, 2023
MEK inhibitors and methods of their use
EXELIXIS INC0 citations61
VALO HEALTH INC
4 patentsUS11548886B2Jan 10, 2023
Monocyclic compounds useful as GPR120 modulators
VALO HEALTH INC4 citations73
US10865201B2Dec 15, 2020
Bicyclic compounds useful as GPR120 modulators
VALO HEALTH INC4 citations72
US12116362B2Oct 15, 2024
Monocyclic compounds useful as GPR120 modulators
VALO HEALTH INC0 citations61
US11919891B2Mar 5, 2024
Bicyclic compounds useful as GPR120 modulators
VALO HEALTH INC0 citations61